CLINICAL TRIALS PROFILE FOR NIRAPARIB TOSYLATE
✉ Email this page to a colleague
All Clinical Trials for NIRAPARIB TOSYLATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04030559 ↗ | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | Recruiting | Janssen, LP | Phase 2 | 2020-02-25 | This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT04030559 ↗ | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2020-02-25 | This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT04030559 ↗ | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | Recruiting | University of California, Davis | Phase 2 | 2020-02-25 | This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT04481113 ↗ | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | Recruiting | Eli Lilly and Company | Phase 1 | 2021-06-07 | This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive [HR+]) and HER2 negative. Abemaciclib may stop the growth of tumor cells by blocking certain proteins called cyclin-dependent kinases, which are needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working so tumor cells can't repair themselves and grow. Giving abemaciclib and niraparib together before surgery may make the tumor smaller. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NIRAPARIB TOSYLATE
Condition Name
| Condition Name for NIRAPARIB TOSYLATE | |
| Intervention | Trials |
| Anatomic Stage II Breast Cancer AJCC v8 | 1 |
| Prognostic Stage IIIB Breast Cancer AJCC v8 | 1 |
| DNA Damage Response Gene Mutation | 1 |
| Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for NIRAPARIB TOSYLATE
Trials by Country
Clinical Trial Progress for NIRAPARIB TOSYLATE
Clinical Trial Phase
Clinical Trial Sponsors for NIRAPARIB TOSYLATE
Sponsor Name
